文献速递淋巴瘤造血干细胞移植与细胞治疗

抗CD19嵌合抗原受体T细胞疗法治疗里氏转化:一项国际多中心回顾性研究

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
PubMed 文献 · J Clin Oncol · 2024-03-29

该国际多中心回顾性研究纳入69例接受抗CD19嵌合抗原受体T细胞(CAR-T)治疗的里氏转化(RT)患者,中位年龄64岁,既往治疗中位4线。总缓解率63%,完全缓解率46%;中位随访24个月时中位无进展生存期4.7个月、2年无进展生存率29%,中位总生存期8.5个月、2年总生存率38%。结论认为CAR-T对RT患者显示出临床疗效。

要点

  • 69例RT患者接受CAR-T,总缓解率63%,完全缓解率46%。
  • 中位无进展生存期4.7个月,2年无进展生存率29%;中位总生存期8.5个月,2年总生存率38%。
  • ≥3级细胞因子释放综合征11例(16%),≥3级免疫效应细胞相关神经毒性综合征25例(37%)。

核心结论

  • 作者结论认为CAR-T对里氏转化患者显示出临床疗效。

研究设计与样本

  • 国际多中心回顾性研究,纳入接受CAR-T治疗的里氏转化患者69例,中位年龄64岁(范围27-80岁)。
  • 患者既往针对慢性淋巴细胞白血病和/或里氏转化的治疗中位4线(范围1-15线),58例(84%)既往接受过Bruton酪氨酸激酶抑制剂和/或BCL2抑制剂治疗。
  • 所用CAR-T产品为阿基仑赛44例(64%)、替沙仑赛17例(25%)、利索基仑赛7例(10%)、brexucabtagene autoleucel 1例(1%)。
  • 无进展生存期与总生存期自CAR-T输注日期起估算,采用描述性统计与建模分析评估与生存的关联。

主要发现

  • 总缓解率为63%,其中46%达到完全缓解。
  • 中位随访24个月后,中位无进展生存期4.7个月(95%CI 2.0-6.9),2年无进展生存率29%(95%CI 18-41)。
  • 中位总生存期8.5个月(95%CI 5.1-25.4),2年总生存率38%(95%CI 26-50)。
  • 达到完全缓解的患者中位缓解持续时间27.6个月(95%CI 14.5-未达到)。
  • 11例(16%)发生≥3级细胞因子释放综合征,25例(37%)发生≥3级免疫效应细胞相关神经毒性综合征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Outcomes for Richter transformation (RT) are poor with current therapies. The efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) for RT are not established. METHODS: We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. RESULTS: Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80). Patients had a median of four (range, 1-15) previous lines of therapy for CLL and/or RT, including previous Bruton tyrosine kinase inhibitor and/or BCL2 inhibitor therapy in 58 (84%) patients. The CAR-T product administered was axicabtagene ciloleucel in 44 patients (64%), tisagenlecleucel in 17 patients (25%), lisocabtagene maraleucel in seven patients (10%), and brexucabtagene autoleucel in one patient (1%). Eleven patients (16%) and 25 patients (37%) experienced grade ≥3 cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, respectively. The overall response rate was 63%, with 46% attaining a complete response (CR). After a median follow-up of 24 months, the median PFS was 4.7 months (95% CI, 2.0 to 6.9); the 2-year PFS was 29% (95% CI, 18 to 41). The median OS was 8.5 months (95% CI, 5.1 to 25.4); the 2-year OS was 38% (95% CI, 26 to 50). The median duration of response was 27.6 months (95% CI, 14.5 to not reached) for patients achieving CR. CONCLUSION: CAR-T demonstrates clinical efficacy for patients with RT.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kittai AS, Bond D, Huang Y, et al. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. J Clin Oncol. 2024. PMID: 38552193. doi:10.1200/JCO.24.00033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。